Join
Live feed
·
PRReleasevia Quantisnow
Replimune Group Inc. logo

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
REPL· Replimune Group Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REPL (Replimune Group Inc.) and more on Quantisnow.